Search Ripretinib Image A broad spectrum inhibitor of KIT and PDGFRA for GIST Ripretinib is an orally administered switch-control kinase inhibitor engineered using our proprietary drug discovery platform and developed for the treatment of gastrointestinal stromal tumor, or GIST. While approved kinase inhibitors control certain initiating and drug resistance-causing mutations in KIT and PDGFRA, the kinases that drive disease progression in most GIST patients, these approved drugs fail to inhibit all known mutations. We designed ripretinib to improve the treatment of GIST patients by inhibiting the full spectrum of the known mutations in KIT and PDGFRA. Ripretinib is a KIT and PDGFRA switch-control kinase inhibitor that blocks initiating and resistance KIT mutations in exons 9, 11, 13, 14, 17, and 18 known to be present in GIST patients. QINLOCK similarly inhibits the primary initiating PDGFRA mutations occurring in exons 12 and 18 and also inhibits wild-type PDGFRA that is subject to amplification in cancers. We are focused on exploring the full potential of ripretinib to benefit people with GIST. Changing the Treatment of GIST Ripretinib in ≥4ᵗʰ Line GIST Related Presentations and Publications U.S. Indication and Important Safety Information About QINLOCK twitter linkedin CONTACT US Main navigation Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3116 Preclinical Pipeline Expanded Access Our Medicine QINLOCK® (ripretinib) Who We Are Management Board of Directors Join Us Open Positions Footer Utility Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement © 2021 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.